- Home
- OZ vs NLSP Comparison
OZ vs NLSP Comparison
Compare OZ & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- NLSP
- Stock Information
- Founded
- OZ 2020
- NLSP 2015
- Country
- OZ United States
- NLSP Switzerland
- Employees
- OZ N/A
- NLSP N/A
- Industry
- OZ
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- OZ
- NLSP Health Care
- Exchange
- OZ Nasdaq
- NLSP Nasdaq
- Market Cap
- OZ 254.2M
- NLSP 243.8M
- IPO Year
- OZ N/A
- NLSP 2021
- Fundamental
- Price
- OZ $63.71
- NLSP $4.27
- Analyst Decision
- OZ
- NLSP
- Analyst Count
- OZ 0
- NLSP 0
- Target Price
- OZ N/A
- NLSP N/A
- AVG Volume (30 Days)
- OZ 3.6K
- NLSP 29.8K
- Earning Date
- OZ 01-01-0001
- NLSP 10-18-2024
- Dividend Yield
- OZ N/A
- NLSP N/A
- EPS Growth
- OZ N/A
- NLSP N/A
- EPS
- OZ N/A
- NLSP N/A
- Revenue
- OZ $1,700,000.00
- NLSP N/A
- Revenue This Year
- OZ N/A
- NLSP N/A
- Revenue Next Year
- OZ N/A
- NLSP N/A
- P/E Ratio
- OZ N/A
- NLSP N/A
- Revenue Growth
- OZ N/A
- NLSP N/A
- 52 Week Low
- OZ $42.75
- NLSP $4.08
- 52 Week High
- OZ $81.75
- NLSP $40.60
- Technical
- Relative Strength Index (RSI)
- OZ 34.15
- NLSP 32.24
- Support Level
- OZ $69.01
- NLSP $4.72
- Resistance Level
- OZ $67.96
- NLSP $5.36
- Average True Range (ATR)
- OZ 0.95
- NLSP 0.58
- MACD
- OZ -0.94
- NLSP 0.00
- Stochastic Oscillator
- OZ 0.00
- NLSP 8.17
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.